AI Article Synopsis

  • The study aims to find alternative laboratory parameters to differentiate between acute hepatitis B and chronic hepatitis B with an acute flare, particularly in regions where HBV infection is common.
  • Significant differences were observed in clinical and laboratory findings between patients with acute self-limited hepatitis B and chronic hepatitis B, notably in the levels of HBV-DNA, HBeAg, and alpha-fetoprotein.
  • Combining IgM anti-HBc with other markers like HBV-DNA and HBeAg enhanced diagnostic accuracy, achieving a high predictive value for diagnosing acute self-limited hepatitis B.

Article Abstract

Background And Aim: In areas with high or intermediate endemicity for chronic hepatitis B virus (HBV) infection, it is difficult to distinguish acute hepatitis B (AHB) from chronic hepatitis B with an acute flare (CHB-AF) in patients whose prior history of HBV infection has been unknown. The present study aimed to screen laboratory parameters other than immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) to discriminate between the two conditions.

Methods: A retrospective and prospective study was conducted in patients first presenting clinically as HBV-related acute hepatitis to sort out acute self-limited hepatitis B (ASL-HB). Then, clinical and laboratory profiles were compared between patients with ASL-HB and CHB-AF. Parameters closely associated with ASL-HB were chosen to evaluate sensitivity, specificity, accuracy, positive predictive values and negative predictive values for diagnosing AHB.

Results: There were significant differences between patients with ASL-HB and CHB-AF in relation to clinical and laboratory aspects, with many outstanding differences in levels of serum HBV-DNA, hepatitis B e antigen (HBeAg) and alpha-fetoprotein (AFP) as well as IgM anti-HBc. In particular, there was a greater difference between the two groups in low levels of HBeAg (ratio of the optical density of the sample to the cut-off value [S/CO] <20) than in negativity for HBeAg (42.7% and 13.5% vs 49.3% and 45.9%). 1:10 000 IgM anti-HBc had a sensitivity and specificity of 96.2% and 93.1%, respectively, for predicting ASL-HB. Combining it with AFP, HBeAg or HBV-DNA could improve diagnostic power. A combination of IgM anti-HBc, HBV-DNA and HBeAg had a predictive value of 98.9% and a negative predictive value of 100.0%, similar to that of a combination of IgM anti-HBc and HBV-DNA. Adding AFP to the combinations of IgM anti-HBc and HBV-DNA or HBeAg could further heighten the positive predictive value. The positive predictive value and negative predictive value of the combination of IgM anti-HBc, HBV-DNA and AFP were both 100.0%.

Conclusions: (i) There are significant differences with respect to clinical, biochemical, immunological and virological aspects between ASL-HB and CHB-AF. (ii) Of several diagnostic combinations, IgM anti-HBc jointing HBV-DNA is most effective and most practicable in distinguishing ASL-HB from CHB-AF. (iii) A low HBeAg level is more useful than negative HBeAg in differential diagnosis between ASL-HB and CHB-AF. (iv) In those patients with a high level of IgM anti-HBc, serum AFP level >10x upper reference limit could rule out a probability of ASL-HB.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1746.2008.05600.xDOI Listing

Publication Analysis

Top Keywords

acute hepatitis
12
chronic hepatitis
12
hepatitis
9
hepatitis acute
8
acute flare
8
hbv infection
8
igm anti-hbc
8
clinical laboratory
8
patients asl-hb
8
asl-hb chb-af
8

Similar Publications

Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on the efficacy of novel biomarkers for AKI detection and management.

View Article and Find Full Text PDF

Prognostic factors in severe dengue patients: A multi-center retrospective cohort study.

PLoS Negl Trop Dis

January 2025

Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, School of Medicine, College of Medicine, Center for Tropical Medicine and Infectious Disease Research, Kaohsiung Medical University, Kaohsiung, Taiwan (R.O.C.).

Background/purpose: Early detection of severe dengue (SD) and appropriate management are crucial in reducing the case fatality rate. The objective of this study was to investigate the clinical characteristics of SD and identify independent risk factors associated with mortality among SD patients.

Methods: A retrospective study was conducted at two medical center hospitals between 2002 and 2019, involving patients aged ≧18 years with laboratory-confirmed SD.

View Article and Find Full Text PDF

Background: Alanine aminotransferase (ALT) frequently elevates in chronic hepatitis B patients stopping nucleos(t)ide analogs (NAs).

Aims: To clarify the association between ALT elevation and HBsAg seroclearance after NA withdrawal.

Methods: This multicenter cohort study reviewed consecutive patients discontinuing NA between 2004/04/01 and 2022/05/24.

View Article and Find Full Text PDF

Hepatitis B virus infection and its treatment in Eastern Ethiopia.

World J Hepatol

January 2025

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan.

Hepatitis B virus (HBV) infection causes acute and chronic hepatitis, compensated and decompensated cirrhosis, and hepatocellular carcinoma worldwide. The actual status of HBV infection and its treatment in certain regions of Asian and African countries, including Ethiopia, has not been well-documented thus far. Antiviral therapy for HBV infection can prevent the progression of HBV-related liver diseases and decrease the HBV-related symptoms, such as abdominal symptoms, fatigue, systemic symptoms and others.

View Article and Find Full Text PDF

Background & Aims: Acute-on-chronic liver failure (ACLF) is a complex syndrome with limited treatment options. This study aims to investigate the impact of artificial liver support system (ALSS) on the one-year prognosis of patients with Hepatitis B virus (HBV)-associated ACLF.

Method: A retrospective study was conducted on 239 patients with HBV-ACLF in Nanfang Hospital from January 2016 to June 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!